Abstract CT015: Results from a phase I/II study with the HDAC inhibitor entinostat in combination with high-dose interleukin-2 in renal cell carcinoma patients (CTEP#7870)
Year: 2016
Type: conference-abstract
Source: Cancer Research
Institutions: Indiana University Indianapolis, University of Southern California, USC Norris Comprehensive Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, The Ohio State University, Roswell Park Comprehensive Cancer Center, National Institutes of Health, National Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2501969367